These 2 biotech stocks could see double-digit upside over the next year.
Read MoreGenerex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a […]
Read MoreIt seems that the only news anybody really cares about right now is the trade war. China announced yesterday that it would impose $60 billion of retaliatory tariffs against the U.S. after the Trump administration increased already imposed duties from 10% to 25% at the end of last week. That has propelled the market to […]
Read MoreAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients […]
Read MoreThese 3 stocks look like bargains at these levels and could soon surge far higher.
Read MoreBoth have catalysts coming up that could make them prime candidates for a buyout.
Read MoreThis small but promising biotech recently had its U.S. debut and analysts say it could deliver a triple-digit return over the next twelve months.
Read MoreThis biotech could see its first drug approved later this year, and it could send the stock skyrocketing.
Read MoreThe index may look overbought, but these 5 stocks could still be a good bet now according to two experts.
Read MoreYou may not know these 2 biotechs, but both are on the cusp of delivering therapies that could send their stocks soaring.
Read MoreOncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples […]
Read MoreNot all penny stocks are created equal, and these 2 stocks under $2 are worth looking at now.
Read MoreCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company’s lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical […]
Read MoreSenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal […]
Read MoreThese 2 biotechs could see massive gains this year. Here’s why.
Read More